Eko Health developed the algorithm with Rochester, Minn.-based Mayo Clinic. The AI stethoscope will allow clinicians to detect low EF — when the heart does not efficiently pump blood — in about 15 seconds during routine exams.
The approval represents a milestone in the early detection of heart disease, the company said. Traditional heart failure detection methods, such as echocardiography, are often unavailable in primary care settings. This means many early-stage cases go undiagnosed until symptoms worsen and result in hospital visits.
“The ability to identify a hidden, potentially life-threatening heart condition using a tool that primary care and subspecialist clinicians are familiar with — the stethoscope — can help us prevent hospitalizations and adverse events,” Paul Friedman, MD, chair of cardiovascular medicine at Mayo Clinic, said in an April 2 news release. “Importantly, since a stethoscope is small and portable, this technology can be used in urban and remote locations, and hopefully help address care in underserved areas.”
Heart failure affects more than 6 million people nationwide, about half of whom have low EF.
Learn more here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
